Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of hederagenin and its glucoside in preparation of medicine for treating cerebral apoplexy

A technology for helexin and cerebral apoplexy, which is applied in the field of medicine and can solve the problems such as helexin and its glycosides that have not yet been seen

Inactive Publication Date: 2018-04-06
CHINA PHARM UNIV
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] There is no report about the use of helexin and its glycosides in the prevention and treatment of stroke

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of hederagenin and its glucoside in preparation of medicine for treating cerebral apoplexy
  • Application of hederagenin and its glucoside in preparation of medicine for treating cerebral apoplexy
  • Application of hederagenin and its glucoside in preparation of medicine for treating cerebral apoplexy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Embodiment 1: The pharmacological action of helexin and its glycosides

[0043] 1. Effect on survival time of mice after cerebral ischemia induced by bilateral ligation of common carotid artery and vagus nerve

[0044] 160 Kunming mice were randomly divided into 16 groups according to body weight and sex: model group and hedera saponin or saponin administration group with serial number 1-15. The mice in the treatment group were given 50 mg / kg / d of helexin or saponin by intragastric administration, and the mice in the model group were given an equal volume of 0.5% CMC-Na by intragastric administration for 2 consecutive weeks. 0.5 hours after the last gavage, the mice were superficially anesthetized with ether, and the bilateral common carotid arteries and vagus nerves were quickly ligated. The survival time of the mice was observed and recorded, and the differences in the survival time of the mice in each group were compared.

[0045]Experimental results: the survival t...

Embodiment 2

[0052] Embodiment 2: Preparation and pharmacological action of an extract containing helexin or its glycosides

[0053] Part 1: Preparation of Extract

[0054] Preparation method one 5kg of dry Lonicera chinense medicinal material, reflux extraction with 70% ethanol for 3 times, 2h each time, filter, combine the filtrate, reclaim the solvent under reduced pressure to obtain extractum (get partly dried to obtain total extract 1), add appropriate amount of water to suspend , filter, and load the sample on D101 macroporous resin, start gradient elution from 10%, 30%, 50%, 70%, 90% ethanol, and monitor whether the eluate contains Decaisoside E, Honeysuckle saponin B or Dipsacus saponin B, any of the three appear in the eluent and start to collect until all three are eluted from the resin and stop collecting. Concentrate and dry this part of the eluent to obtain the extract of Lonicera tomentosa Object 1.

[0055] Preparation method two 5kg of dry Lonicera chinensis medicinal ...

Embodiment 3

[0075] Embodiment 3: pharmaceutical preparation

[0076]1. Tablet: 5g of helexin or saponin or Lonicera tomentosa extract of serial number 1-15, 50g of starch, 3g of magnesium stearate. Preparation process: take the hedera saponin or saponin or Lonicera tomentosa extract of serial number 1-15, add starch and magnesium stearate, mix evenly, make granules, dry, and compress into tablets.

[0077] 2. Capsules: 5g of hedera saponin or saponin or Lonicera tomentosa extract with serial number 1-15, 50g of starch, 3g of magnesium stearate. Preparation process: take the hedera saponin or saponin or Lonicera chrysanthemum extract of serial number 1-15, add starch and magnesium stearate, mix evenly, make granules, dry, and pack into capsules.

[0078] 3. Injection: 1g of hedera saponin or saponin or Lonicera tomentosa extract with serial number 1-15, appropriate amount of sodium chloride for injection. Preparation process: take the hedera saponin or saponin or Lonicera tomentosa extra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of hederagenin and its glucoside in preparation of a medicine for treating cerebral apoplexy. The invention provides the application of hederagenin or saponin with a sequence number being 1-15 in preparation of the medicine for treating cerebral apoplexy, mice processed by the hederagenin or saponin with the sequence number being 1-15 is subjected to bilateral common carotid artery ligation and global cerebral ischemia due to pneumogastric nerve, and mice viability time is obviously longer than that of a model group; in a suture method MCAO model, the hederagenin or saponin with the sequence number being 1-15 is used for intervention, the cerebral ischemia volume of the rat is obviously improved, and the result displays that the hederagenin or saponinwith the sequence number being 1-15 has good protection effect for global cerebral ischemia and rat focal cerebral ischemia, so that technicians in the field has full reason to believe that the hederagenin or saponin with the sequence number being 1-15 has good treatment effect for cerebral arterial thrombosis.

Description

technical field [0001] The invention belongs to the field of medicine, relates to new applications of known natural products, in particular to the application of helexin and its glycosides in the preparation of medicines for preventing and treating cerebral apoplexy. Background technique [0002] Hederagenin is a pentacyclic triterpenoid compound with the chemical name (3β,4α)-3,23-dihydroxyolean-12-ene-28-acid, and the molecular formula is C 30 h 48 o 4 . Hedera saponin is a glycosidation product of hedera saponin. [0003] Hedera saponin and hedera saponin are abundant in natural resources, and are widely distributed in Disperaceae, Lonicaceae, Ranunculaceae, Araliaceae and Patrinaceae and other plants, and have good development advantages. The applicant has conducted systematic research on hederagenin and hedera saponin, and found that hedera saponin and hedera saponin have various pharmacological effects, have preventive value for various diseases, and have broad cli...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/56A61K31/704A61P25/00A61P9/10
CPCA61K31/56A61K31/704
Inventor 齐炼文李萍
Owner CHINA PHARM UNIV